Table XX: Distribution of characteristics of disease cohort by data source\*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | AS cohort | | | Non-AS cohort | |
|  | Market Scan  N= | MPCD  N= | Medicare  N= | MPCD  N= | Medicare  N= |
| Age in years, Mean (std) |  |  |  |  |  |
| Female |  |  |  |  |  |
| Race |  |  |  |  |  |
| Combines co-morbidity index |  |  |  |  |  |
| <0 |  |  |  |  |  |
| 0 |  |  |  |  |  |
| 1 |  |  |  |  |  |
| 2 |  |  |  |  |  |
| ≥3 |  |  |  |  |  |
| Charlson Index |  |  |  |  |  |
| 0 |  |  |  |  |  |
| 1 |  |  |  |  |  |
| 2 |  |  |  |  |  |
| 3 |  |  |  |  |  |
| 4 and more |  |  |  |  |  |
| Charlson Index, mean (std) |  |  |  |  |  |
| Myocardial Infarction |  |  |  |  |  |
| Coronary heart disease |  |  |  |  |  |
| Peripheral vascular disorder |  |  |  |  |  |
| Cerebrovascular disease |  |  |  |  |  |
| Dementia |  |  |  |  |  |
| Chronic pulmonary disease |  |  |  |  |  |
| Rheumatologic disease |  |  |  |  |  |
| Peptic ulcer disease |  |  |  |  |  |
| Mild liver disease |  |  |  |  |  |
| Diabetes |  |  |  |  |  |
| Diabetes with chronic complications |  |  |  |  |  |
| Hemiplegia or paraplegia |  |  |  |  |  |
| Renal Disease |  |  |  |  |  |
| Malignancy, including leukemia and lymphoma |  |  |  |  |  |
| Moderate or severe liver disease |  |  |  |  |  |
| Metastatic solid tumor |  |  |  |  |  |
| AIDS |  |  |  |  |  |
| Other co-morbidities |  |  |  |  |  |
| Hypertension |  |  |  |  |  |
| Metabolic syndrome |  |  |  |  |  |
| Non-alcoholic fatty liver disease |  |  |  |  |  |
| Osteoporosis |  |  |  |  |  |
| Health utilization |  |  |  |  |  |
| Prostate specific antigen (men only) |  |  |  |  |  |
| PAP smear (women only) |  |  |  |  |  |
| Mammography (women only) |  |  |  |  |  |
| Any hospitalization |  |  |  |  |  |
| Number of physician visit, mean(std) |  |  |  |  |  |

\*using 6 month baseline period, unless otherwise indicated

Table XXa: Distribution of characteristics of by exposure for Market Scan data\*

|  |  |  |  |
| --- | --- | --- | --- |
|  | TNF  N= | DMARDS  N= | NSAIDS or no exposure  N= |
| Age in years, Mean (std) |  |  |  |
| Female, % |  |  |  |
| Race |  |  |  |
| Combines co-morbidity index, % |  |  |  |
| <0 |  |  |  |
| 0 |  |  |  |
| 1 |  |  |  |
| 2 |  |  |  |
| ≥3 |  |  |  |
| Charlson Index, % |  |  |  |
| 0 |  |  |  |
| 1 |  |  |  |
| 2 |  |  |  |
| 3 |  |  |  |
| 4 and more |  |  |  |
| Charlson Index, mean (std) |  |  |  |
| Myocardial Infarction, % |  |  |  |
| Coronary heart disease |  |  |  |
| Peripheral vascular disorder |  |  |  |
| Cerebrovascular disease |  |  |  |
| Dementia |  |  |  |
| Chronic pulmonary disease |  |  |  |
| Rheumatologic disease |  |  |  |
| Peptic ulcer disease |  |  |  |
| Mild liver disease |  |  |  |
| Diabetes |  |  |  |
| Diabetes with chronic complications |  |  |  |
| Hemiplegia or paraplegia |  |  |  |
| Renal Disease |  |  |  |
| Malignancy, including leukemia and lymphoma |  |  |  |
| Moderate or severe liver disease |  |  |  |
| Metastatic solid tumor |  |  |  |
| AIDS |  |  |  |
| Other co-morbidities |  |  |  |
| Hypertension |  |  |  |
| Metabolic syndrome |  |  |  |
| Non-alcoholic fatty liver disease |  |  |  |
| Osteoporosis |  |  |  |
| Health utilization |  |  |  |
| Prostate specific antigen (men only) |  |  |  |
| PAP smear (women only) |  |  |  |
| Mammography (women only) |  |  |  |
| Any hospitalization |  |  |  |
| Number of physician visit, mean(std) |  |  |  |

\*using 6 month baseline period, unless otherwise indicated

Table XXb: Distribution of characteristics of by exposure for MPCD data\*

|  |  |  |  |
| --- | --- | --- | --- |
|  | TNF  N= | DMARDS  N= | NSAIDS or no exposure  N= |
| Age in years, Mean (std) |  |  |  |
| Female, % |  |  |  |
| Race |  |  |  |
| Combines co-morbidity index, % |  |  |  |
| <0 |  |  |  |
| 0 |  |  |  |
| 1 |  |  |  |
| 2 |  |  |  |
| ≥3 |  |  |  |
| Charlson Index, % |  |  |  |
| 0 |  |  |  |
| 1 |  |  |  |
| 2 |  |  |  |
| 3 |  |  |  |
| 4 and more |  |  |  |
| Charlson Index, mean (std) |  |  |  |
| Myocardial Infarction, % |  |  |  |
| Coronary heart disease |  |  |  |
| Peripheral vascular disorder |  |  |  |
| Cerebrovascular disease |  |  |  |
| Dementia |  |  |  |
| Chronic pulmonary disease |  |  |  |
| Rheumatologic disease |  |  |  |
| Peptic ulcer disease |  |  |  |
| Mild liver disease |  |  |  |
| Diabetes |  |  |  |
| Diabetes with chronic complications |  |  |  |
| Hemiplegia or paraplegia |  |  |  |
| Renal Disease |  |  |  |
| Malignancy, including leukemia and lymphoma |  |  |  |
| Moderate or severe liver disease |  |  |  |
| Metastatic solid tumor |  |  |  |
| AIDS |  |  |  |
| Other co-morbidities |  |  |  |
| Hypertension |  |  |  |
| Metabolic syndrome |  |  |  |
| Non-alcoholic fatty liver disease |  |  |  |
| Osteoporosis |  |  |  |
| Health utilization |  |  |  |
| Prostate specific antigen (men only) |  |  |  |
| PAP smear (women only) |  |  |  |
| Mammography (women only) |  |  |  |
| Any hospitalization |  |  |  |
| Number of physician visit, mean(std) |  |  |  |

\*using 6 month baseline period, unless otherwise indicated

Table XXc: Distribution of characteristics of by exposure for Medicare data\*

|  |  |  |  |
| --- | --- | --- | --- |
|  | TNF  N= | DMARDS  N= | NSAIDS or no exposure  N= |
| Age in years, Mean (std) |  |  |  |
| Female, % |  |  |  |
| Race |  |  |  |
| Combines co-morbidity index, % |  |  |  |
| <0 |  |  |  |
| 0 |  |  |  |
| 1 |  |  |  |
| 2 |  |  |  |
| ≥3 |  |  |  |
| Charlson Index, % |  |  |  |
| 0 |  |  |  |
| 1 |  |  |  |
| 2 |  |  |  |
| 3 |  |  |  |
| 4 and more |  |  |  |
| Charlson Index, mean (std) |  |  |  |
| Myocardial Infarction, % |  |  |  |
| Coronary heart disease |  |  |  |
| Peripheral vascular disorder |  |  |  |
| Cerebrovascular disease |  |  |  |
| Dementia |  |  |  |
| Chronic pulmonary disease |  |  |  |
| Rheumatologic disease |  |  |  |
| Peptic ulcer disease |  |  |  |
| Mild liver disease |  |  |  |
| Diabetes |  |  |  |
| Diabetes with chronic complications |  |  |  |
| Hemiplegia or paraplegia |  |  |  |
| Renal Disease |  |  |  |
| Malignancy, including leukemia and lymphoma |  |  |  |
| Moderate or severe liver disease |  |  |  |
| Metastatic solid tumor |  |  |  |
| AIDS |  |  |  |
| Other co-morbidities |  |  |  |
| Hypertension |  |  |  |
| Metabolic syndrome |  |  |  |
| Non-alcoholic fatty liver disease |  |  |  |
| Osteoporosis |  |  |  |
| Health utilization |  |  |  |
| Prostate specific antigen (men only) |  |  |  |
| PAP smear (women only) |  |  |  |
| Mammography (women only) |  |  |  |
| Any hospitalization |  |  |  |
| Number of physician visit, mean(std) |  |  |  |

\*using 6 month baseline period, unless otherwise indicated

Table XX: Prevalence of comorbidities by disease cohort and data source using all available prior data.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Outcome categories** | **Specific manifestation** | **AS cohort** | | | **Non-AS cohort** | |
| **Market Scan** | **MPCD** | **Medicare** | **MPCD** | **Medicare** |
|  | N |  |  |  |  |  |
| Cardiac disease | Conduction block |  |  |  |  |  |
| Aortic insufficiency/aortic regurgitation |  |  |  |  |  |
| Myocardial infarction |  |  |  |  |  |
| Osteoporotic fracture | Clinical vertebral fracture |  |  |  |  |  |
| Non-vertebral osteoporotic fracture (hip, pelvis, femur, humerus, distal radius/ulna) |  |  |  |  |  |
| Neurological disease | Cauda equina syndrome |  |  |  |  |  |
| Spinal cord compression |  |  |  |  |  |
| Lung disease | Apical pulmonary fibrosis |  |  |  |  |  |
| Interstitial lung disease (sensitive definition) |  |  |  |  |  |
| Restrictive lung disease |  |  |  |  |  |
| Kidney disease | IgA nephropathy |  |  |  |  |  |
| Amyloidosis |  |  |  |  |  |
| Nephrotic syndrome |  |  |  |  |  |
| PsO/PsA | Psoriasis |  |  |  |  |  |
| Psoriatic arthritis |  |  |  |  |  |
| Inflammatory bowel disease | Ulcerative colitis |  |  |  |  |  |
| Crohn’s disease |  |  |  |  |  |
| Uveitis | Uveitis |  |  |  |  |  |
| Infection | Hospitalized |  |  |  |  |  |
| Opportunistic |  |  |  |  |  |
| Malignancy | Solid tumor |  |  |  |  |  |
| Hematologic |  |  |  |  |  |
| NMSC |  |  |  |  |  |

Table XX: Prevalence of comorbidities by data source and exposure using all available prior data.

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Outcome categories** | **Specific manifestation** | **MPCD** | | | **Marketscan** | | | **Medicare** | | |
| **TNF** | **DMARDS** | **NSAIDS or no exposure** | **TNF** | **DMARDS** | **NSAIDS or no exposure** | **TNF** | **DMARDS** | **NSAIDS or no exposure** |
|  | N |  |  |  |  |  |  |  |  |  |
| Cardiac disease | Conduction block |  |  |  |  |  |  |  |  |  |
| Aortic insufficiency/aortic regurgitation |  |  |  |  |  |  |  |  |  |
| Myocardial infarction |  |  |  |  |  |  |  |  |  |
| Osteoporotic fracture | Clinical vertebral fracture |  |  |  |  |  |  |  |  |  |
| Non-vertebral osteoporotic fracture (hip, pelvis, femur, humerus, distal radius/ulna) |  |  |  |  |  |  |  |  |  |
| Neurological disease | Cauda equina syndrome |  |  |  |  |  |  |  |  |  |
| Spinal cord compression |  |  |  |  |  |  |  |  |  |
| Lung disease | Apical pulmonary fibrosis |  |  |  |  |  |  |  |  |  |
| Interstitial lung disease (sensitive definition) |  |  |  |  |  |  |  |  |  |
| Restrictive lung disease |  |  |  |  |  |  |  |  |  |
| Kidney disease | IgA nephropathy |  |  |  |  |  |  |  |  |  |
| Amyloidosis |  |  |  |  |  |  |  |  |  |
| Nephrotic syndrome |  |  |  |  |  |  |  |  |  |
| PsO/PsA | Psoriasis |  |  |  |  |  |  |  |  |  |
| Psoriatic arthritis |  |  |  |  |  |  |  |  |  |
| Inflammatory bowel disease | Ulcerative colitis |  |  |  |  |  |  |  |  |  |
| Crohn’s disease |  |  |  |  |  |  |  |  |  |
| Uveitis | Uveitis |  |  |  |  |  |  |  |  |  |
| Infection | Hospitalized |  |  |  |  |  |  |  |  |  |
| Opportunistic |  |  |  |  |  |  |  |  |  |
| Malignancy | Solid tumor |  |  |  |  |  |  |  |  |  |
| Hematologic |  |  |  |  |  |  |  |  |  |
| NMSC |  |  |  |  |  |  |  |  |  |

Table XX: Outcome incidence per 1,000 person-years by data source and exposure.

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Outcome categories** | **Specific manifestation** | **MPCD** | | | **Marketscan** | | | **Medicare** | | |
| **TNF** | **DMARDS** | **NSAIDS or no exposure** | **TNF** | **DMARDS** | **NSAIDS or no exposure** | **TNF** | **DMARDS** | **NSAIDS or no exposure** |
|  | Person-years |  |  |  |  |  |  |  |  |  |
| Cardiac disease | Conduction block |  |  |  |  |  |  |  |  |  |
| Aortic insufficiency/aortic regurgitation |  |  |  |  |  |  |  |  |  |
| Myocardial infarction |  |  |  |  |  |  |  |  |  |
| Osteoporotic fracture | Clinical vertebral fracture |  |  |  |  |  |  |  |  |  |
| Non-vertebral osteoporotic fracture (hip, pelvis, femur, humerus, distal radius/ulna) |  |  |  |  |  |  |  |  |  |
| Neurological disease | Cauda equina syndrome |  |  |  |  |  |  |  |  |  |
| Spinal cord compression |  |  |  |  |  |  |  |  |  |
| Lung disease | Apical pulmonary fibrosis |  |  |  |  |  |  |  |  |  |
| Interstitial lung disease (sensitive definition) |  |  |  |  |  |  |  |  |  |
| Restrictive lung disease |  |  |  |  |  |  |  |  |  |
| Kidney disease | IgA nephropathy |  |  |  |  |  |  |  |  |  |
| Amyloidosis |  |  |  |  |  |  |  |  |  |
| Nephrotic syndrome |  |  |  |  |  |  |  |  |  |
| PsO/PsA | Psoriasis |  |  |  |  |  |  |  |  |  |
| Psoriatic arthritis |  |  |  |  |  |  |  |  |  |
| Inflammatory bowel disease | Ulcerative colitis |  |  |  |  |  |  |  |  |  |
| Crohn’s disease |  |  |  |  |  |  |  |  |  |
| Uveitis | Uveitis |  |  |  |  |  |  |  |  |  |
| Infection | Hospitalized |  |  |  |  |  |  |  |  |  |
| Opportunistic |  |  |  |  |  |  |  |  |  |
| Malignancy | Solid tumor |  |  |  |  |  |  |  |  |  |
| Hematologic |  |  |  |  |  |  |  |  |  |
| NMSC |  |  |  |  |  |  |  |  |  |